B of A Securities Maintains Buy on ResMed, Lowers Price Target to $250
Portfolio Pulse from jenniferd'souza@benzinga.com
B of A Securities analyst Lyanne Harrison maintains a Buy rating on ResMed (NYSE:RMD) but lowers the price target from $260 to $250.
August 04, 2023 | 3:50 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ResMed's price target has been lowered from $260 to $250 by B of A Securities, though the Buy rating is maintained.
The lowering of the price target by B of A Securities could potentially create a negative sentiment among investors, which might put downward pressure on the stock price. However, the maintained Buy rating indicates that the analyst still sees potential upside, which could counterbalance the negative sentiment.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100